TPST - Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types | Benzinga
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. The presentation covered experimental results that corroborated clinical biomarker data from patients with advanced solid tumor cancers treated in a Phase 1 trial with TPST-1120 showing increased expression of select immune-related genes and elevated plasma Free Fatty Acid (FFA) levels associated with clinical response. TPST-1120 is an oral, selective PPAR? antagonist in clinical development that has shown promising results, including positive data from a randomized study in first-line hepatocellular carcinoma (HCC) patients compared to the standard of care.
"Data presented at the SITC Spring Scientific Meeting bolster our mechanistic understanding of PPAR? blockade in cancer patients and reinforce a basis for the ongoing late-stage clinical development of TPST-1120," said Sam Whiting, M.D., Ph.D., chief medical officer and ...